TL;DR: On 21 May 2026, the EMA’s CHMP adopted a positive opinion recommending oral semaglutide tablets — the Wegovy pill — for approval across the EU, in four strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg. That recommendation now goes to the European Commission for a final decision, after which pricing and reimbursement are set country by country. The pill already has FDA approval and a US launch, as the first oral GLP-1 receptor agonist ever approved for weight management. In the OASIS 4 trial, the 25 mg dose produced substantial weight loss, though which number you see quoted (16.6% or 13.6%) depends on how the trial counted people who did not take every dose.
What just happened in Europe
If you have been tracking semaglutide research from the EU side, this is the headline: oral semaglutide is no longer just a US story. On 21 May 2026, the Committee for Medicinal Products for Human Use (CHMP) — the EMA body that reviews medicines before they reach the European Commission — adopted a positive opinion recommending a variation to Wegovy’s existing marketing authorisation. The variation adds a new pharmaceutical form and a new route of administration: tablets for oral use, in four strengths of 1.5 mg, 4 mg, 9 mg, and 25 mg.
That is a CHMP recommendation, not yet a market authorization. The next formal step is a decision from the European Commission, which typically follows a positive CHMP opinion within a couple of months and is largely procedural once the opinion is adopted. After that, each EU member state runs its own pricing and reimbursement process, so the calendar for when the pill actually reaches a pharmacy counter — and at what price — will vary considerably by country. Novo Nordisk has indicated plans to bring the oral pill to markets outside the US later in 2026, though exact country-by-country timing depends on those national processes.
- 1
December 22, 2025
FDA approves the Wegovy pill (oral semaglutide 25 mg) for chronic weight management and to reduce the risk of major adverse cardiovascular events — the first oral GLP-1 receptor agonist approved for weight management.
- 2
Early January 2026
US retail launch begins.
- 3
21 May 2026
EMA CHMP adopts a positive opinion recommending Wegovy tablets in four strengths for the EU.
- 4
Next: European Commission decision
The opinion moves to the EC for a formal decision, then to per-country pricing and reimbursement negotiations.
The US side of the story, briefly
The EU news did not appear out of nowhere. In the US, the FDA approved the Wegovy pill on December 22, 2025, for chronic weight management and to reduce the risk of major adverse cardiovascular events, with retail availability beginning in early January 2026. It was, and remains, the first oral GLP-1 receptor agonist approved anywhere for weight management — as distinct from Rybelsus, an earlier oral semaglutide product approved only for type 2 diabetes at lower doses. The Wegovy pill and Rybelsus share the same underlying delivery technology, but they are different products, at different doses, cleared for different indications.
If you want the foundational mechanism of semaglutide itself — how it engages the GLP-1 receptor across the pancreas, brain, and stomach — that groundwork is covered in our What is Semaglutide? overview. This article picks up specifically where the injectable story leaves off: how you get a peptide into the bloodstream through the gut at all.
How a peptide survives being swallowed
Peptides are, in general, terrible oral drug candidates. Stomach acid and digestive enzymes exist specifically to break proteins and peptides down into amino acids, and a peptide like semaglutide travelling through the gut unprotected would largely be destroyed before it could be absorbed. Injectable semaglutide sidesteps this entirely by going straight into subcutaneous tissue. The oral tablet has to solve the digestion problem directly.
The solution is SNAC (salcaprozate sodium), an absorption enhancer co-formulated into the tablet alongside semaglutide.
Even with SNAC doing its job, oral bioavailability is low and inconsistent from dose to dose and person to person — nothing like the near-complete absorption you get from a subcutaneous injection. That is the direct explanation for why the oral maintenance dose is 25 mg once daily, while the injectable maintenance dose is 2.4 mg once weekly. It is not a stronger dose; it is a much less efficient delivery route, and the tablet strength compensates for what gets lost along the way.
That inefficiency is also why the dosing conditions on the label are strict, not optional.
The four strengths line up with a stepwise titration, similar in spirit to the injectable schedule covered in our semaglutide dosing and titration guide: treatment starts at the lowest strength, and the dose is increased roughly every 30 days as tolerated, up to the 25 mg target. On the label, the tablet is taken once daily on an empty stomach, swallowed whole with no more than about 120 mL of plain water — no other liquid — followed by a wait of at least 30 minutes before eating, drinking anything else, or taking other oral medications. Because absorption happens predominantly in the stomach and depends on that concentrated SNAC microenvironment, food, other liquids, or other pills too soon afterward can meaningfully cut into how much semaglutide actually gets absorbed that day.
What OASIS 4 actually found — and why you’ll see two different numbers
The efficacy case behind both the FDA approval and the CHMP opinion rests heavily on OASIS 4, a phase 3 trial of oral semaglutide 25 mg once daily in adults with obesity, or overweight with at least one weight-related comorbidity, over 64 weeks.
Read enough coverage of OASIS 4 and you will run into two different weight-loss figures, and both are correct — they are just answering slightly different questions.
Both estimands from the OASIS 4 phase 3 trial (64 weeks).
The 16.6% figure is the trial-product estimand: the mean weight loss among participants who actually adhered to the assigned treatment for the full 64 weeks, against a placebo group of 2.7%. It answers “what happens if someone takes this as prescribed.” The 13.6% figure is the treatment-policy estimand — essentially an intention-to-treat analysis that includes everyone randomized to the drug, whether or not they completed the trial or took every dose, against a placebo figure of 2.2%. It answers “what happens across everyone who started treatment, including the people who stopped early or missed doses.”
Neither number is wrong, and neither is cherry-picked; regulators report both because they answer different practical questions. The trial-product estimand is closer to what an individual who sticks with treatment can expect. The treatment-policy estimand is closer to what a population-level rollout — including everyone who starts and doesn’t finish — actually delivers. Roughly one in three participants who adhered to oral semaglutide lost at least 20% of their body weight, compared with a low single-digit percentage on placebo — a scale of effect broadly in line with what the injectable version has shown in the STEP program, which we cover in the semaglutide overview.
Oral pill or weekly injection?
The Wegovy pill does not replace the injectable pen so much as offer an alternative route to a similar destination. Efficacy in OASIS 4 is in the same range as the injectable STEP trials, but the two forms differ in dosing burden, gastrointestinal tolerability patterns, and the practical friction of the empty-stomach rule versus a once-weekly injection. We go deep on that head-to-head comparison, including who tends to prefer which route, in oral vs. injectable semaglutide. If gastrointestinal side effects are your main hesitation about either form, our GLP-1 side effect management guide covers what to expect and how it is typically handled. And if you are weighing semaglutide against other GLP-1 and dual-agonist molecules more broadly, our semaglutide vs. tirzepatide vs. retatrutide comparison lays out the wider field.
What this means if you are in Europe
For EU readers, the practical takeaway right now is timing, not access. A positive CHMP opinion is a strong, well-established signal — the European Commission decision that follows is largely procedural — but it is a different milestone from having a box on a pharmacy shelf with a price attached. Reimbursement and launch timing will differ by country, the same way it did for injectable Wegovy. Worth watching for over the coming months: the European Commission’s formal decision, then individual national health-technology-assessment and pricing outcomes as they roll out market by market.
Related reading
Frequently asked questions
Is the Wegovy pill available in Europe yet?
Not yet, as of this writing. The EMA’s CHMP adopted a positive opinion on 21 May 2026 recommending approval, but that opinion still needs a formal European Commission decision, followed by separate pricing and reimbursement processes in each EU member state before it reaches pharmacies.
How is the Wegovy pill different from Rybelsus?
Both use the same SNAC-based oral delivery technology and the same active ingredient, semaglutide, but they are different products. Rybelsus is approved for type 2 diabetes at lower doses (up to 14 mg), while the Wegovy pill is approved specifically for weight management at a higher 25 mg maintenance dose.
Why is the oral dose 25 mg when the injectable dose is only 2.4 mg?
Because oral bioavailability is low and variable — most of an oral dose is never absorbed, even with the SNAC absorption enhancer helping it along. The much larger oral dose compensates for that inefficiency; it is not a stronger effective exposure, just a less efficient route to a comparable one.
Why do OASIS 4 headlines report both 16.6% and 13.6% weight loss?
They come from two different ways of analyzing the same trial. 16.6% reflects participants who adhered to treatment for the full 64 weeks (trial-product estimand); 13.6% reflects everyone randomized to the drug, including those who stopped early or missed doses (treatment-policy estimand). Both are accurate; they just answer different questions about who is included.
What are the four tablet strengths for?
They form a titration path rather than four separate products. Treatment starts at 1.5 mg, then steps up through 4 mg and 9 mg, typically at roughly monthly intervals as tolerated, before reaching the 25 mg target dose used in the OASIS 4 efficacy data.
Does the pill need to be taken on an empty stomach?
Yes. The label calls for taking it first thing, with no more than a small sip of plain water, then waiting at least 30 minutes before eating, drinking anything else, or taking other oral medications. Because SNAC’s effect is localized and short-lived, and absorption happens mainly in the stomach, food or other liquids taken too soon can reduce how much semaglutide is actually absorbed.
References
- Novo Nordisk. “Wegovy® pill (oral semaglutide) FDA approval.” Company announcement, December 22, 2025.
- Novo Nordisk. “Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU.” Company announcement, May 22, 2026.
- European Medicines Agency. Wegovy — opinion on variation to marketing authorisation, adopted 21 May 2026. ema.europa.eu.
- Wharton S, et al. “Oral Semaglutide 25 mg in Adults with Overweight or Obesity” (OASIS 4). New England Journal of Medicine. 2025.
- American Diabetes Association. “Current Understanding of SNAC as an Absorption Enhancer: The Oral Semaglutide Experience.” Clinical Diabetes. 2024.
Last updated: June 17, 2026